- Home
- SPRY
as 11-26-2025 3:39pm EST
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.1B | IPO Year: | N/A |
| Target Price: | $31.25 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.66 - $18.90 | Next Earning Date: | 11-10-2025 |
| Revenue: | $142,772,000 | Revenue Growth: | 5459.66% |
| Revenue Growth (this year): | -7.67% | Revenue Growth (next year): | 193.13% |
Latest ARS Pharmaceuticals Inc. News
SPRY Breaking Stock News: Dive into SPRY Ticker-Specific Updates for Smart Investing
MT Newswires
11 days ago
ARS Pharmaceuticals Insider Sold Shares Worth $1,476,147, According to a Recent SEC Filing
Simply Wall St.
11 days ago
Why Analysts See the ARS Pharmaceuticals Story Shifting Amid Changing Growth and Market Risks
MT Newswires
2 months ago
ARS Pharmaceuticals Says European Patent Office Upholds Nasal Spray Epinephrine Patent
GlobeNewswire
2 months ago
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
Simply Wall St.
2 months ago
ARS Pharmaceuticals (SPRY) Is Up 5.2% After Securing $250M Term Loan to Accelerate Neffy Launch – Has the Bull Case Changed?
TipRanks
3 months ago
ARS Pharmaceuticals announces real-world evidence on neffy effectiveness
GlobeNewswire
3 months ago
Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis
Insider Monkey
3 months ago
ARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDA
Compare SPRY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SPRY ARS Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.